Physician profile
John Swangim
NPI 1184672727
$872.52
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.78 · 2020: $36.24 · 2021: $63.42 · 2022: $275 · 2023: $452 · 2024: $19.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $144.28 | 2023 | Ortholoc 3di Crosscheck |
| Paratek Pharmaceuticals, INC. | $120.53 | 2022-2023 | Nuzyra |
| Horizon Therapeutics Plc | $113.50 | 2023 | Krystexxa |
| Averitas Pharma INC. | $85.49 | 2023 | Qutenza |
| Orthofix Medical, INC. | $79.44 | 2020-2022 | |
| Organogenesis INC. | $47.21 | 2022 | |
| Bioventus LLC | $32.45 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.03 | 2021-2022 | |
| Smith+Nephew, INC. | $29.43 | 2022 | |
| Dexcom, INC. | $27.98 | 2022 | |
| Innocoll Pharmaceuticals Limited | $25.66 | 2022 | |
| Merck Sharp & Dohme LLC | $23.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.64 | 2022 | |
| Convatec INC. | $19.06 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.82 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.04 | 2019 | |
| Wright Medical Technology, INC. | $13.98 | 2020 | |
| Sanara Medtech INC. | $13.74 | 2022 | |
| Novo Nordisk INC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Swangim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.